Generic Name:
ozanimod
Project Status:
Complete
Therapeutic Area:
Multiple Sclerosis, relapsing - remitting
Manufacturer:
Celgene Inc.
Brand Name:
Zeposia
Project Line:
Reimbursement Review
Project Number:
SR0652-000
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.